The 11 analysts offering 12-month price forecasts for bluebird bio Inc have a median target of 11.00, with a high estimate of 16.18 and a low estimate of 9.00. The median estimate represents a +34.15% increase from the last price of 8.20.
The current consensus among 14 polled investment analysts is to Hold stock in bluebird bio Inc. This rating has held steady since January, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.97
Reporting Date Feb 23
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.